Predicting Treatment Outcomes in Glioblastoma: A Risk Score Model for TMZ Resistance and Immune Checkpoint Inhibition

Predicting Treatment Outcomes in Glioblastoma: A Risk Score Model for TMZ Resistance and Immune Checkpoint Inhibition

Glioblastoma (GBM) presents significant therapeutic challenges due to its invasive nature and resistance to standard chemotherapy, i.e., temozolomide (TMZ). This study aimed to identify gene signatures that predict poor TMZ response and high PD−L1/PD−1 tumor expression, and explore potential sensiti...

Full description

Saved in:
Bibliographic Details
Main Authors: Nazareno Gonzalez, Melanie Perez Küper, Matias Garcia Fallit, Alejandro J. Nicola Candia, Jorge A. Peña Agudelo, Maicol Suarez Velandia, Ana Clara Romero, Guillermo Agustin Videla-Richardson, Marianela Candolfi
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Biology
Subjects:
glioblastoma
immune microenvironment
differentially expressed genes
risk score model
temozolomide resistance
Online Access:https://www.mdpi.com/2079-7737/14/5/572
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2079-7737/14/5/572

Similar Items